Ischemic stroke occurs when a blood vessel supplying the brain is obstructed.
Consider stroke in any patient presenting with sudden focal neurological deficit or any alteration in level of consciousness.
Rapid evaluation is essential for sure of time-sensitive treatments.
Determine if patient's symptoms are due to stroke and exclude stroke mimics (eg migraine, hypertensive encephalopathy, hypoglycemia, seizures or post-ictal paresis); identify other conditions requiring immediate intervention and determine the potential causes of stroke.


  • Determine if patient’s symptoms are due to stroke, identify other conditions requiring immediate intervention and determine the potential causes of stroke


  • Time of symptom onset is the single most important piece of historical information
    • Stroke onset defined as the last time patient was symptom-free
  • Obtain circumstances around the development of symptoms and features that may point to other potential causes of symptoms
  • Identify risk factors for arteriosclerosis and cardiac disease; medications, conditions that may predispose to bleeding complications; history of drug abuse, infection, migraine, seizure, trauma, oral contraceptive use or pregnancy

Physical Examination

  • Complete physical examination including vital signs, oxygen saturation and body temperature
  • Brief but thorough neurologic exam


Clinical Stroke Score

  • National Institute of Health (NIH) Stroke Scale
    • Helps quantify the degree or severity of neurological deficit and may identify possible location of lesion/occlusion
    • Facilitates communication between healthcare professionals and may provide prognostic information
    • May identify patients eligible for interventions and potential risk for complications

Laboratory Tests

Routine Laboratory Tests

  • Blood glucose, complete blood count (CBC) with platelet count, renal function tests, serum electrolytes, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), D-dimer, fibrinogen
  • Cardiac biomarkers may be done to confirm or rule out acute coronary syndrome if needed

Perform the following tests, if required:

  • Toxicology screen, blood alcohol level
  • Arterial blood gas (if hypoxia is suspected)
  • Liver function tests
  • Pregnancy test
  • Chest radiograph (if lung disease is suspected)
  • Lumbar puncture (if subarachnoid hemorrhage is suspected and computed tomography (CT) is negative for blood)
  • Electroencephalography (EEG), if seizures are suspected


  • Should be done on all admitted patients suspected of acute ischemic strokes
  • Performed within 20-25 minutes of arrival in the emergency room who may be candidates for IV Alteplase and/or mechanical thrombectomy 
  • It is not recommended to utilize additional imaging beyond computed tomography, computed tomography angiography, magnetic resonance angiography and other perfusion studies in patients for mechanical thrombectomy in <6 hours
  • Non-contrast Cranial Computed Tomography (CT)
    • Recommended to differentiate ischemic from hemorrhagic stroke or other structural brain lesions that may mimic stroke
    • A computed tomography scan may be normal within the 1st 24 hours of ischemia but will show hemorrhages from onset of stroke
    • Mandatory before initiating any specific therapy to treat acute ischemic stroke
    • Alberta Stroke Program Early Computed Tomography Score (ASPECTS) helps in the detection of early ischemic changes and should be evaluated in patients who are candidates for intravenous thrombolysis
    • Hyperdense MCA CT should not be used as criteria to withhold IV Alteplase
  • Cranial Computed Tomography Angiography (CTA)
    • May be used in suspected intracranial large vessel occlusion patients without renal impairment history
    • Serum creatinine concentration may be deferred if patient does not present with renal impairment 
  • Magnetic Resonance Imaging (MRI) of the Brain
    • Magnetic resonance imaging is more sensitive and specific for diagnosis of ischemic stroke and determination of the extent of reversible or irreversible cerebral ischemia especially for stroke within 3-8 hours
    • Important in patients with unusual presentations, stroke varieties, or in whom stroke mimics are suspected but not clarified on computed tomography
    • It is not recommended to use MRI to exclude cerebral microbleeds before IV Alteplase administration
  • Cranial Magnetic Resonance Imaging with Diffusion-Weighted Imaging (DWI)
    • Highly sensitive in detecting early cerebral ischemic changes in acute stroke patients
  • Vascular Imaging
    • Computed tomography and magnetic resonance angiography, transcranial Doppler ultrasonography, carotid duplex sonography and catheter angiography have been used to detect intracranial or extracranial vessel abnormalities


Intravenous recombinant tissue plasminogen activator (rt-PA) should only be administered under the following conditions:

  • Physician and staff with expertise in acute stroke management, in delivering thrombolysis and in monitoring for complications
  • Immediate access to high-resolution imaging (eg noncontrast CT scan) facilities which are available 24 hours/day and staff trained and experienced in interpreting the results
  • Facility has the means to treat potential complications (eg intracerebral hemorrhage)
  • Intravenous rt-PA is given only to patients satisfying specific inclusion and exclusion criteria

Patient Inclusion Criteria

  • Patients with within 3-4.5 hours of acute ischemic stroke symptom onset or last known well or baseline state
  • Ischemic stroke with measurable neurological deficit by clinical assessment confirmed through neuroimaging and shows no signs of hemorrhage
  • Medically eligible patients ≥18 years of age 
  • Initiation of treatment with rt-PA is within 3 hours after symptom onset; may extend time window up to 4.5 hours after symptom onset in selected patients
  • Mild with disabling stroke symptoms to severe stroke symptoms
  • Patients with mild stroke presenting in 3- to 4.5-hour window period may be given IV Alteplase
  • Known case of sickle cell disease presenting with acute ischemic stroke
  • Patients with blood pressures that can be lowered safely to <185/110 mmHg with antihypertensive agents

Patient Exclusion Criteria

Clinical Contraindications

  • Onset of stroke >4.5 hours prior to planned start of treatment
  • Neurologic deficit is minor or spontaneously and rapidly improving
  • Symptoms of stroke suggestive of subarachnoid hemorrhage, regardless of a computed tomography result
  • Hypertension: Systolic blood pressure (SBP) >185 mmHg and diastolic blood pressure (DBP) >110 mmHg on repeated measurements or if aggressive treatment is required to lower blood pressure
  • In the setting of middle cerebral artery (MCA) stroke, an obtunded or comatose state may be a relative contraindication
  • Signs of active bleeding or acute trauma (ie fracture) on examination

History Contraindications

  • Major surgery (eg recent intracranial or spinal surgery) or serious trauma within the last 2 weeks
  • History of intracranial hemorrhage
  • Prior stroke or serious head injury in the preceding 3 months
  • Gastrointestinal or urinary tract hemorrhage within 21 days
  • Structural gastrointestinal malignancy
  • Infective endocarditis
  • Arterial puncture at a noncompressible site within the preceding 7 days or lumbar puncture within the last 3 days
  • Untreated cerebral aneurysm, arteriovenous malformation (AVM) or brain tumor
  • Clinical presentation suggestive of post-MI pericarditis
  • Patient is taking oral anticoagulants and with INR >1.7 or prothrombin time >15 seconds
  • Patient has received heparin within the last 48 hours and has an elevated activated partial thromboplastin time greater than the upper limit of normal
  • Patient has received low molecular weight heparin within the last 24 hours
  • Known hereditary or acquired hemorrhagic diathesis or unsupported coagulation factor deficiency
  • Known case or suspected case of aortic arch dissection

Laboratory Contraindications

  • Platelet count <100,000 mm3
  • INR >1.7 and elevated activated partial thromboplastin time (>1.5x normal)
  • Positive pregnancy test

Radiology Contraindications

  • Intracranial hemorrhage
  • Large area of low attenuation consistent with an infarcted brain (time of symptom onset may have been earlier)
  • Intracranial tumor, aneurysm, arteriovenous malformation or other space-occupying lesion

Relative Exclusion Criteria

  • Patients >80 years of age
  • Taking oral anticoagulants, regardless of INR level
    • May be re-evaluated if lab tests (eg activated partial thromboplastin time, INR, platelet count) are normal or if last dose of non-vitamin K oral anticoagulant was taken >48 hours ago in patients with normal renal function
  • Severe stroke (National Institutes of Health Stroke Scale Score >25) or radiological evidence of infarction involving >1/3 of the middle cerebral artery territory
  • Combined prior history of stroke and diabetes
  • Seizure at stroke onset
  • Pregnancy or possible pregnancy
  • >10 cerebral microbleeds on MRI
  • Acute myocardial infarction (MI) occurred in the past 3 months is a STEMI involving the left anterior myocardium
  • History of gastrointestinal or genitourinary bleeding
  • Initial glucose <50 mg/dL or >400 mg/dL (<2.7 mmol/L or >22.2 mmol/L)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2016
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
01 Mar 2016
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
16 Dec 2018
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.